secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000914475-23-000003
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine and Voyager form $175M upfront gene therapy collaboration for GBA1 and rare CNS targets
--------------------------------------------------------------------------------

- $175M upfront: ~$136M cash to Voyager plus $39M equity at $8.88/share (50% premium to 30-day VWAP).
- Up to $1.5B in development milestones (GBA1 ≤$985M; each of three new CNS programs ≤$175M) plus commercial milestones & royalties.
- Voyager can opt for 50/50 US co-dev/co-commercial on GBA1 after Phase 1 data; otherwise tiered royalties (low-double-digit to 20% US).
- Three new rare CNS gene therapy programs leverage Voyager's TRACER capsids; Neurocrine funds all development costs.
- Jude Onyia, Ph.D. (Neurocrine CSO), to join Voyager's board effective closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/nbix-20230108.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer